Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience

Turunc V., Ari E., Guven B., Tabendeh B., Yildiz A.

TRANSPLANTATION PROCEEDINGS, cilt.51, sa.7, ss.2308-2311, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51 Sayı: 7
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.transproceed.2019.01.149
  • Dergi Adı: TRANSPLANTATION PROCEEDINGS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2308-2311
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background. This study aimed to determine whether de novo, prolonged-release tacrolimus- (PR-tacro) based immunosuppressive regimen affected graft and patient survival when compared to an immediate-release, twice-daily, tacrolimus- (IR-tacro) based regimen in kidney transplant recipients. We also aimed to determine the difference between the frequency of side effects, including diabetes control, in study groups.